The effect of vasopressors on mortality in critically ill patients with COVID-19: A systematic review and meta-analysis

Maria Mermiri MD[1*], Georgios Mavrovounis MD[2*], Eleni Laou MD, PhD[1], Nikolaos Papagiannakis MD, PhD[3], Ioannis Pantazopoulos MD, PhD[2], Athanasios Chalkias MD, PhD[1,4]

[1] Department of Anesthesiology, Faculty of Medicine, University of Thessaly, Larisa, Greece

[2] Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, Larisa, Greece

[3] First Department of Neurology, Eginition University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

[4] Outcomes Research Consortium, Cleveland, OH 44195, United States

*Authors contributed equally and share first authorship

Corresponding author: Prof. Athanasios Chalkias, University Hospital of Larisa, Department of Anesthesiology, 41110, Biopolis, Larisa, Greece. Tel.: +30 2413502953, Fax.: +30 2413501017, Email: thanoschalkias@yahoo.gr

ORCID:

Athanasios Chalkias: 0000-0002-7634-4665

ABSTRACT

Purpose: The effect of vasopressors on mortality of critically ill patients with COVID-19 has not been studied extensively.

Methods: A systematic search of PubMed, Scopus, and clinicaltrials.gov was conducted for relevant articles until January 2022. Eligibility criteria were randomized controlled and non-randomized trials. The primary outcome was all-cause mortality at 28 days or 30 days. The quality of studies was assessed using the MINORS tool. Paired meta-analysis was used to estimate the pooled risk ratios along with their 95% Confidence Interval.

Results: In total, 33 studies were included. Twenty-one studies with a total population of 7900 individuals provided data on mortality. Patients who received vasopressors were statistically significantly more likely to die compared to those who did not receive vasopressor therapy [RR (95%CI): 4.26 (3.15, 5.76); $p<0.001$]. This result remained statistically significant regardless of the in-hospital setting. In-hospital and 30-day mortality were statistically significantly higher in patients who received vasopressors [RR (95%CI): 4.60 (2.47, 8.55); $p<0.001$ and RR (95%CI): 2.97 (1.72, 5.14); $p<0.001$, respectively]. Four studies provided data on specific vasopressors; the highest mortality rate was observed in patients treated with vasopressin or epinephrine, while patients receiving angiotensin-II as a sole or second-line vasopressor agent had the lowest mortality rate. Also, analysis of 10 studies with a total population of 3519 individuals revealed that patients who received vasopressors were statistically significantly more likely to experience acute kidney injury [RR (95%CI): 3.17 (2.21, 4.54); $p<0.001$].

Conclusion: Vasopressors have detrimental effect on survival of critically ill patients with COVID-19.

Key words: covid-19; critically ill; hemodynamics; vasopressor; intensive care; mortality

TAKE-HOME MESSAGE

- The effect of vasopressors on mortality of critically ill patients with COVID-19 has not been studied extensively.
- Vasopressors have detrimental effect on survival of critically ill patients with COVID-19.

1. INTRODUCTION

Mounting evidence suggest that COVID-19 should be perceived as a new entity with its own characteristics and distinct pathophysiology, including complex immuno-inflammatory, thrombotic, and parenchymal derangements [1]. The cytokine storm and the dysregulation of host response are more severe in COVID-19-related acute respiratory distress syndrome (ARDS) than in ARDS of other causes [2-4]. SARS-CoV-2 not only infects the respiratory tract, but also injures the vascular endothelium and epithelium [5,6], and thus, COVID-19 can affect many systems of the human body.

Most critically ill patients with COVID-19 need hemodynamic support that is usually guided by the current, non-covid, surviving sepsis campaign guidelines recommending the use of vasopressors to optimize mean arterial pressure (MAP) and cardiac output and provide adequate organ perfusion [7,8]. Most of these medications improve the hemodynamic function through enhancement of the adrenergic pathway; however, they may have important side-effects due to excessive adrenergic stimulation [9-11]. Of note, exogenous catecholamines can have a pronounced impact on inflammation and immunosuppression, metabolism, endothelial lesion, platelet activation, and coagulation [12]. As critically ill patients with COVID-19 are characterized by a similar pathophysiological substrate, exogenous vasopressors could further dysregulate their physiological cascades and aggravate outcome [13]. We therefore performed a systematic review and meta-analysis to investigate the effect of vasopressors on mortality of critically ill patients with COVID-19.

2. MATERIAL AND METHODS

The protocol was registered in the PROSPERO international prospective register of systematic reviews on 13 December 2021 (CRD42021297595). This systematic review and meta-analysis were reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist (Appendix A) [14].

2.1 Inclusion and exclusion criteria

The inclusion criteria of the current systematic review and meta-analysis were: (1) randomized controlled trials (RCTs) and observational studies; (2) critically ill patients admitted to the intensive care (ICU) or high dependency unit (HDU); (3) adults (≥ 18 years old) hospitalized primarily for COVID-19; (4) SARS-CoV-2 infection confirmed by reverse transcription polymerase chain reaction test of nasopharyngeal or oropharyngeal samples; and (5) vasopressor administration. We excluded animal studies, case reports, review papers, editorials, abstracts, white papers, and non-English literature. We also excluded studies pediatric patients, non-ICU/HDU patients, and patients who did not receive vasopressor therapy.

2.2 Outcomes of interest

The primary outcome was all-cause mortality at 28 days or 30 days, or when lacking these data, all-cause mortality as reported by the authors. Secondary outcomes was to investigate (1) the hemodynamic profiles of patients at first measuring point and after six hours [heart rate, MAP, central venous pressure (CVP), urinary output, blood lactate levels, cardiac output or cardiac index, systemic vascular resistance index, central venous oxygen saturation, oxygen delivery index, and oxygen

consumption index]; (2) the number of participants who achieved the target MAP (≥65 mmHg); (3) time to achieve the target MAP; (4) adverse events including arrhythmia, acute myocardial infarction, cardiac arrest, acute mesenteric ischemia, digital ischemia, acute kidney injury (AKI); (5) vasopressor-free days; (6) ICU length of stay; (7) duration of mechanical ventilation; (8) ventilator free days; (9) hospital length of stay; and (10) all-cause mortality at 90-days.

2.3 Search strategy

The search strategy was intended to explore all available published and unpublished studies until January 20th, 2022. A comprehensive initial search was employed in PubMed (MEDLINE), Scopus, and clinicaltrials.gov databases by two independent investigators (MM, GM) followed by an analysis of the textwords contained in Title/Abstract and indexed terms. A second search was conducted by combining free text words (vasopressor, epinephrine, norepinephrine, phenylephrine, vasopressin, dopamine, angiotensin-II, covid-19, critically ill, intensive care) and indexed terms with Boolean operators. Finally, a third search was conducted with the reference lists of all identified reports and articles for additional studies. Appendix B presents the exact search algorithm used for all databases.

2.4 Data extraction

The data from each study were extracted by two independent authors (MM, GM) with a customized format. Any disagreements between the two independent authors were resolved by four other authors (EL, IP, NP, AC). Publication details (authors, year), study information (design, population, department of admission, follow-up, inclusion-exclusion criteria, number of cases/cohort-size, and subgroups),

hemodynamic profile (heart rate, MAP, CVP, urinary output, blood lactate levels, cardiac output or cardiac index, systemic vascular resistance index, central venous oxygen saturation, oxygen delivery index, oxygen consumption index) at first measuring point and six hours after vasopressor use, the number of participants who achieved the target MAP and time to achieve the target MAP, adverse events, vasopressor-free days, ICU length of stay, hospital length of stay, duration of mechanical ventilation, ventilator-free days, all-cause mortality in all groups at 28 or 30 days, and all-cause mortality at 90 days were extracted in a pre-designed excel spreadsheet. The definition used for AKI and the mortality follow-up timepoints for each study are presented in Appendix C1. Authors of studies with missing data were contacted in an attempt to obtain relevant data.

2.5 Assessment of methodological quality

Articles identified for retrieval were assessed by two independent authors (MM, GM) for methodological quality before inclusion in the review using standardized critical appraisal tools. The quality of the included observational studies was assessed using the MINORS tool [15], while the Risk of Bias 2.0 (RoB 2.0) tool was used for RCTs [16]. Any disagreements between the authors appraising the articles were resolved through discussion with the other authors.

2.6 Data analysis and Synthesis

A paired meta-analysis was used to estimate the pooled risk ratios (RR) along with their 95% Confidence Interval (95% CI). Based on the presence of statistical heterogeneity, the meta-analysis was conducted according to fixed- or random effect models. The statistical heterogeneity was estimated by the use of the Cochran's Q and

I^2 indices. When I^2>50% and/or P_Q<0.10, the random effects model was used, otherwise the fixed effects model was implemented [17]. Funnel plots as well as the Begg's test were used to determine the existence of publication bias [18,19]. The statistical significance was set at p<0.05. All statistical analyses were performed in Review Manager (Rev-Man) [Computer program], Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

3. RESULTS

Altogether, 809 relevant citations were identified and screened, while 87 studies were included in our final assessment for possible data extraction (Fig. 1). In total, data extraction was possible in 33 studies [20-52].

3.1 Study characteristics

All the 33 included studies were observational in their design [20-52]. The studies originated from multiple countries, with 13 of coming from institutions located in the USA [20,21,23,32-35,38,42,43,45,48,51]. Nineteen studies included only patients admitted in the ICU [20,22,24,25,27,30-32,35-39,43-47,52], five studies included patients admitted in a COVID-19-dedicated HDU [28,29,33,34,42], eight studies included patients who were admitted in both HDU and ICU [21,23,26,40,41,48,49,51], and one study included Emergency Department patients who were later admitted either in the HDU of ICU [50]. Thirty studies included data about patients who received *vs.* patients who did not receive vasopressors [20-37,39-48,50,52]. Moreover, three studies included patients who received angiotensin-II [38,49,51] and, out of those, two compared the use of angiotensin-II with other

vasopressors [49,51] (Appendix C2). Table 1 summarizes the main characteristics of the included studies.

3.2 Synthesis including all patients

3.2.1 Primary outcome

Twenty-one out of the 33 included studies provided data on hospital mortality in patients who received *vs.* patients who did not receive vasopressors, resulting in a total population of 7900 individuals [25,27,31-37,39-48,50,52]. Due to high heterogeneity (I^2: 94%, P_Q<0.001), the random-effects model was implemented. Patients who received vasopressors were statistically significantly more likely to die compared to those who did not receive vasopressor therapy [RR (95%CI): 4.26 (3.15, 5.76); p<0.001] (Figure 2). Visual inspection of the funnel plot (Appendix D1) and Begg's test (p=0.86) did not reveal significant publication bias.

We performed subgroup analyses based on the department of admission. The results for all three subgroups, namely ICU [RR (95%CI): 3.45 (2.32, 5.13); p < 0.001], HDU [RR (95%CI): 6.25 (4.63, 8.44); p < 0.001], and ICU + HDU [RR (95%CI): 5.52 (2.51, 12.15); p < 0.001], remained statistically significant for higher mortality rates in patients who received vasopressors.

Subgroup analyses were also performed based on the mortality follow-up timepoints. Only the in-hospital and 30-day mortality subgroups had three or more studies that allowed data extraction and analysis. The in-hospital and 30-day mortality were statistically significantly higher in patients who received vasopressors [RR (95%CI): 4.60 (2.47, 8.55); p<0.001 and RR (95%CI): 2.97 (1.72, 5.14); p<0.001, respectively].

3.2.1.1 Effect of major vasopressors on mortality

Four studies provided data on mortality based on the specific vasopressor(s) administered [38,43,49,51]. The highest mortality rate was observed in patients treated with vasopressin or epinephrine (78% and 76%, respectively) [43]. Three of those studies investigated the role of angiotensin-II as a sole or second-line vasopressor agent [38,49,51]. These studies showed the lowest mortality rate. The relevant data are depicted in Table 2.

3.2.2 Secondary outcomes

3.2.2.1 Acute Kidney Injury

Ten studies provided data on AKI in patients who received *vs.* patients who did not receive vasopressors, resulting in a total population of 3519 individuals [21-23,25-30,44]. Due to high heterogeneity (I^2: 92%, P_Q<0.001), the random-effects model was implemented. Patients who received vasopressors were statistically significantly more likely to experience AKI compared to those who did not receive vasopressor therapy [RR (95%CI): 3.17 (2.21, 4.54); p<0.001] (Figure 3).

Subgroup analyses were performed based on the definition of AKI that was used in the included studies. Only the subgroup with patients at all KDINGO stages included more than three studies, allowing for meta-analysis to be performed. Specifically, patients who received vasopressors were more likely to experience AKI when compared to those who did not receive vasopressor therapy [RR (95%CI): 2.29 (1.67-3.14); p < 0.001] (Figure 4).

3.2.2.2 Other secondary outcomes

No data were identified for the remaining secondary outcomes.

3.3 Risk of bias, quality of evidence

The overall quality of the studies, as assessed by the MINORS tool, ranged between moderate and high. The exact score for each study is available in Appendix C3. In addition, visual inspection of the funnel plot (Appendix D2) and the Begg's test (p=0.18) did not reveal significant publication bias for the studies included in the AKI analysis. All included studies were observational non-randomized studies, and as a result according to GRADE criteria they have a low grade in quality of evidence.

4. DISCUSSION

Many high-quality RCTs have addressed the effects of vasopressors on the outcomes of non-covid patients, yet their impact on mortality in patients with COVID-19 had not been studied so far. The most important finding of this systematic review and meta-analysis is that vasopressors have detrimental effect on survival of critically ill patients with COVID-19. Although these results are based on published non-randomized evidence, they raise significant concerns for the routine management of these individuals.

Universally, the mortality of critically ill patients with COVID-19 is higher than that of other critically ill patients [53,54]. A main cause for this difference is the characteristics of the SARS-CoV-2 infection, which can rapidly affect other organs including the cardiovascular system [55]. However, there are no specific guidelines on the hemodynamic support of COVID-19 patients. Although administration of vasopressors is a fundamental treatment of hypotension, the traditional (non-covid) hemodynamic management of shock and the adverse effects of vasoactive agents may be associated with complications and poor outcome in patients with COVID-19. Indeed, the present analysis revealed that critically ill patients with COVID-19 who

receive vasopressors are more likely to die in the hospital or at 30 days compared to those who do not receive vasopressor therapy regardless of the in-hospital setting. Although the association of vasopressors with increased mortality could be coincidental due to the severity of critical illness, catecholamines affect many systems including the immune and hematological systems, the renin-angiotensin-aldosterone system, the cardiovascular and respiratory systems, and others [13], suggesting a complex interplay that can have a detrimental effect on survival.

Of the 33 included studies in this systematic review and meta-analysis, only four studies included data on specific vasopressors. The highest mortality rate was observed in patients receiving vasopressin or epinephrine. Although one can appraise that these patients had severe shock necessitating second- and third-line vasopressors [7], these observations merit further discussion. Epinephrine is well-known for its adverse effects in non-covid and COVID-19 patients [56], but our observations regarding vasopressin are quite interesting. Although vasopressin infusion reduces total norepinephrine-equivalent dose requirements and may be renal and pulmonary vasculature sparing [57], there is evidence showing a pronounced activation of the vasopressin system in COVID-19 patients and that molecular complexes form between the SARS-CoV-2 spike protein, soluble angiotensin-converting enzyme-2 (ACE2), and vasopressin, facilitating cellular infection and aggravating outcome [58,59]. However, data from a small clinical cohort did not show a clinically relevant effect of vasopressin infusion on viral mRNA level in critically ill patients with COVID-19 (but who were not treated with corticosteroids or interleukin-6 antagonists) [57]. The findings of the present analysis suggest that arginine vasopressin agonists might not be a good choice for these individuals. Considering that vasopressin is suggested as a second-line vasopressor in the latest international

guidelines for management of sepsis and septic shock [7], further research is required to establish the therapeutic efficiency of vasopressin in critically ill patients with COVID-19.

Another intriguing finding is the low mortality rate in patients receiving angiotensin-II as a sole or second-line vasopressor agent. Serpa Neto et al. showed a potentially positive effect of angiotensin-II on blood pressure and fraction of inspired oxygen in COVID-19 patients, but they did not collect data regarding treatment with steroids or other drugs, which may have affected their results [49]. Leisman et al. and Ofosu-Barko et al. reported that angiotensin-II treatment was associated with rapid improvement in multiple physiologic indices [38,51]. The rationale for angiotensin-II therapy is based on decreasing the expression of the ACE2 receptors, which can reduce the entry of the COVID-19 virus into cells [60,61]. However, the progressive loss of ACE2 shifts the system to an overall higher angiotensin level due to the impaired ability of ACE2 to degrade it, which may explain the initial hemodynamic stability of patients with COVID-19 [62]. Therefore, exogenous use of angiotensin-II may be harmful in patients with increased endogenous levels. Taking into consideration its potential favorable effects in critically ill patients with COVID-19, randomized controlled trials are needed to further evaluate angiotensin-II for the treatment of COVID-19-related shock.

In non-covid patients, administration of vasopressors is not associated with increased mortality, while prophylactic administration in patients with vasodilatory shock may improve survival [63]. In addition, a Cochrane systematic review found no evidence of substantial differences in total mortality between several vasopressors [64]. Nevertheless, vasopressors are a heterogeneous class of drugs with powerful and immediate haemodynamic effects, and each drug has advantages and disadvantages.

These characteristics are particularly important in patients with COVID-19 who are characterized by unique pathophysiological disturbances and different hemodynamic phenotypes that necessitate a thorough understanding of the underlying complex pathophysiology and careful selection and administration of vasoactive agents.

In COVID-19, the progressive hypoxemia initially increases cardiac output and capillary recruitment, which maintain microcirculatory oxygen-extraction capacity by increasing red blood cell availability (silent hypoxia) [65-67]. However, microcirculatory flow decreases proportionally to the increasing inflammation, hypercoagulation, and thrombosis, resulting in multi-organ failure at later stages [65,68-70]. In the study by Mesquida et al., patients showed alterations in systemic microcirculatory status, and the degree of these alterations correlated with the severity of the respiratory disease [24]. The relationship between MAP and organ blood flow may be different in critically ill patients with COVID-19 and improving only macrocirculation might be inadequate to maintain tissue perfusion. In these patients, vasopressor use can overwhelm endogenous receptor-mediated vessel regulation, further contributing to the loss of hemodynamic coherence [66,71], and therefore, hemodynamic management should focus on optimizing microcirculatory perfusion instead of attaining a predefined MAP target.

4.1 Limitations

This analysis included patients from various settings, i.e., HDU, ICU, and Emergency Department. Consequently, it may have included heterogeneous groups of patients with COVID-19. Due to the lack of randomized controlled trials, the synthesis of all the available knowledge on the specific outcomes was difficult. The

level of heterogeneity was high and the conclusions drawn from this review must be cautious and reserved.

Additionally, no data from the different studies was available to adjust the resulting odds ratios according to age, comorbidities, the presence of septic shock or other known factors that affect ICU mortality. In addition, most of the secondary outcomes could not be assessed. Another limitation is the heterogeneity of definitions of AKI that were used across different studies. Also, many of the included studies were conducted in retrospective fashion. Finally, we did not include non-English publications.

5. CONCLUSIONS

The present systematic review and meta-analysis showed that vasopressor use was associated with an increase in mortality and AKI in critically ill patients with COVID-19, according to published non-randomized evidence. It is worth noting that we found a lower mortality rate in patients receiving angiotensin-II as a sole or second-line vasopressor agent, while the highest mortality rate was observed in patients receiving vasopressin and epinephrine. Further research is required to estimate the correlation of specific vasopressors with adverse effects and mortality in this population.

6. PERSPECTIVES

The results of the present systematic review and meta-analysis suggest for early administration of low-dose vasopressors, with or without inodilator agents, in an effort to avoid excessive doses that could have detrimental effect on survival, especially at later disease stages. An alternative second-line vasopressor may be

angiotensin-II. However, further immediate research is recommended to elucidate the effects of angiotensin-II and other vasopressors acting through pathways other than the adrenergic pathway as sole or second-line vasopressor agents. These agents may be associated with a significant increase in survival.

A possible explanation for the association of vasopressors with mortality may lie in the microcirculation [65-71]. The physiological pulsatile shear stress from normal laminar flow maintains the normal endothelial cell functions and the expression of ACE2s and other anticoagulant/antithrombotic and antioxidant substances [72]. However, dysfunctional endothelium resulting from turbulent flow displays a hypercoagulant/prothrombotic and pro-oxidant state and impairs microcirculatory reactivity and flow [73]. Therapeutic approaches should consider the systemic vascular involvement and include the assessment of microcirculation, allowing individualized, physiology-guided management. Of note, an increased CVP in critically ill patients with COVID-19 may impair venous return and retrogradely increase post-capillary venular pressure which, together with excessive vasopressor doses, impair capillary perfusion and increase the diffusion distance of oxygen [74,75]. Thus, minimizing fluid administration is also crucial for improving tissue perfusion in this population.

Further research and well-designed trials are necessary to investigate the effect of the type (catecholamines *vs.* non-catecholamines), time of administration, and infusion rates of vasopressors in order to develop specific treatment strategies and integrate a more individualized approach in patients with COVID-19.

Acknowledgements: We would like to thank Dr. George L. Anesi, University of Pennsylvania Perelman School of Medicine, for responding to our request for additional study data.

Author contributions: Conceptualization: AC. Data curation: MM, GM. Formal analysis: MM, GM. Methodology: AC, MM, GM, EL, NP, IP. Project administration: AC. Visualization: MM, GM, EL, NP, IP, AC. Writing - original draft: AC. Writing - review & editing: AC, MM, GM, EL, NP, IP.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Sharing Statement: Data can be made available upon request after publication through a collaborative process. Researchers should provide a methodically sound proposal with specific objectives in an approval proposal. Please contact the corresponding author for additional information.

DECLARATIONS

Conflict of interest: On behalf of all authors, the corresponding author states that there is no conflict of interest.

REFERENCES

1. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohé SB, Wiersinga WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T, Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R, Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martín JF, Rubio I (2021) The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 9:622-642. https://doi.org/10.1016/S2213-2600(21)00218-6.
2. Sinha P, Calfee CS, Cherian S, Brealey D, Cutler S, King C, Killick C, Richards O, Cheema Y, Bailey C, Reddy K, Delucchi KL, Shankar-Hari M, Gordon AC, Shyamsundar M, O'Kane CM, McAuley DF, Szakmany T (2020) Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med 8:1209-1218. https://doi.org/10.1016/S2213-2600(20)30366-0.
3. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schröder AS, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber TB (2020) Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med 383:590-592. https://doi.org/10.1056/NEJMc2011400.
4. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de

Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S (2020) Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 173:268-277. https://doi.org/10.7326/M20-2003.

5. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5.
6. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26:1017-1032. https://doi.org/10.1038/s41591-020-0968-3.
7. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Møller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung

CL, Welte T, Zimmerman J, Levy M (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181-1247. https://doi.org/10.1007/s00134-021-06506-y.

8. Botta M, Tsonas AM, Pillay J, Boers LS, Algera AG, Bos LDJ, Dongelmans DA, Hollmann MW, Horn J, Vlaar APJ, Schultz MJ, Neto AS, Paulus F; PRoVENT-COVID Collaborative Group (2021) Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med 9:139-148. https://doi.org/10.1016/S2213-2600(20)30459-8.
9. Dünser MW, Hasibeder WR (2009) Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 24:293-316. https://doi.org/10.1177/0885066609340519.
10. Schmittinger CA, Torgersen C, Luckner G, Schröder DC, Lorenz I, Dünser MW (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38:950-958. https://doi.org/10.1007/s00134-012-2531-2.
11. Bangash MN, Kong ML, Pearse RM (2012) Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol 165:2015-2033. https://doi.org/10.1111/j.1476-5381.2011.01588.x.
12. Hartmann C, Radermacher P, Wepler M, Nußbaum B (2017) Non-Hemodynamic Effects of Catecholamines. Shock 48:390-400. https://doi.org/10.1097/SHK.0000000000000879.

13. Gubbi S, Nazari MA, Taieb D, Klubo-Gwiezdzinska J, Pacak K (2020) Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes Endocrinol 8:978-986. https://doi.org/10.1016/S2213-8587(20)30342-9.
14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71.
15. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https://doi.org/10.1136/bmj.i4919.
16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing

risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898.

17. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558. https://doi.org/10.1002/sim.1186.
18. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101.
19. Mavridis D, Salanti G (2014) How to assess publication bias: funnel plot, trim-and-fill method and selection models. Evid Based Ment Health 17:30. https://doi.org/10.1136/eb-2013-101699.
20. Ionescu F, Zimmer MS, Petrescu I, Castillo E, Bozyk P, Abbas A, Abplanalp L, Dogra S, Nair GB (2021) Extubation Failure in Critically Ill COVID-19 Patients: Risk Factors and Impact on In-Hospital Mortality. J Intensive Care Med 36:1018-1024. https://doi.org/10.1177/08850666211020281.
21. Pelayo J, Lo KB, Bhargav R, Gul F, Peterson E, DeJoy Iii R, Salacup GF, Albano J, Gopalakrishnan A, Azmaiparashvili Z, Patarroyo-Aponte G, Rangaswami J (2020) Clinical Characteristics and Outcomes of Community- and Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System. Cardiorenal Med 10:223-231. https://doi.org/10.1159/000509182.
22. Lowe R, Ferrari M, Nasim-Mohi M, Jackson A, Beecham R, Veighey K, Cusack R, Richardson D, Grocott M, Levett D, Dushianthan A; University Hospital Southampton Critical Care Team and the REACT COVID investigators (2021) Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol 22:92. https://doi.org/10.1186/s12882-021-02296-z.

23. Hansrivijit P, Gadhiya KP, Gangireddy M, Goldman JD (2021) Risk Factors, Clinical Characteristics, and Prognosis of Acute Kidney Injury in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Medicines (Basel) 8:4. https://doi.org/10.3390/medicines8010004.
24. Mesquida J, Caballer A, Cortese L, Vila C, Karadeniz U, Pagliazzi M, Zanoletti M, Pacheco AP, Castro P, García-de-Acilu M, Mesquita RC, Busch DR, Durduran T; HEMOCOVID-19 Consortium (2021) Peripheral microcirculatory alterations are associated with the severity of acute respiratory distress syndrome in COVID-19 patients admitted to intermediate respiratory and intensive care units. Crit Care 25:381. https://doi.org/10.1186/s13054-021-03803-2.
25. Ghosn M, Attallah N, Badr M, Abdallah K, De Oliveira B, Nadeem A, Varghese Y, Munde D, Salam S, Abduljawad B, Saleh K, Elkambergy H, Wahla A, Taha A, Dibu J, Bayrlee A, Hamed F, Rahman N, Mallat J (2021) Severe Acute Kidney Injury in Critically Ill Patients with COVID-19 Admitted to ICU: Incidence, Risk Factors, and Outcomes. J Clin Med 10:1217. https://doi.org/10.3390/jcm10061217.
26. Farooqui MA, Almegren A, Binrushud SR, Alnuwaiser FA, Almegren NM, Alhamied NA, Aloraifi EA, Alothman AM, Aldafas MA, Ardah HI, Alhejaili FF (2021) Incidence and Outcome of Acute Kidney Injury in Patients Hospitalized With Coronavirus Disease-19 at a Tertiary Care Medical Center in Saudi Arabia. Cureus 13:e18927. https://doi.org/10.7759/cureus.18927.
27. Neves PDMM, Sato VAH, Mohrbacher S, Ferreira BMC, Oliveira ÉS, Pereira LVB, Bales AM, Nardotto LL, Ferreira JN, Machado DJ, Bassi E, Silva-Júnior A, Chocair PR, Cuvello-Neto AL (2021) Acute Kidney Injury Due to

COVID-19 in Intensive Care Unit: An Analysis From a Latin-American Center. Front Med (Lausanne) 8:620050. https://doi.org/10.3389/fmed.2021.620050.

28. Bernardo J, Gonçalves J, Gameiro J, Oliveira J, Marques F, Duarte I, Branco C, Costa C, Carreiro C, Fonseca JN, Braz S, Lopes JA (2021) The impact of transient and persistent acute kidney injury in hospital mortality in COVID-19 patients. J Bras Nefrol In press. https://doi.org/10.1590/2175-8239-JBN-2021-0123.
29. Hardenberg JB, Stockmann H, Aigner A, Gotthardt I, Enghard P, Hinze C, Balzer F, Schmidt D, Zickler D, Kruse J, Körner R, Stegemann M, Schneider T, Schumann M, Müller-Redetzky H, Angermair S, Budde K, Weber-Carstens S, Witzenrath M, Treskatsch S, Siegmund B, Spies C, Suttorp N, Rauch G, Eckardt KU, Schmidt-Ott KM (2021) Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. Kidney Int Rep 6:905-915. https://doi.org/10.1016/j.ekir.2021.01.011.
30. Geri G, Darmon M, Zafrani L, Fartoukh M, Voiriot G, Le Marec J, Nemlaghi S, Vieillard-Baron A, Azoulay E (2021) Acute kidney injury in SARS-CoV2-related pneumonia ICU patients: a retrospective multicenter study. Ann Intensive Care 11:86. https://doi.org/10.1186/s13613-021-00875-9.
31. Ñamendys-Silva SA, Alvarado-Ávila PE, Domínguez-Cherit G, Rivero-Sigarroa E, Sánchez-Hurtado LA, Gutiérrez-Villaseñor A, Romero-González JP, Rodríguez-Bautista H, García-Briones A, Garnica-Camacho CE, Cruz-Ruiz NG, González-Herrera MO, García-Guillén FJ, Guerrero-Gutiérrez MA, Salmerón-González JD, Romero-Gutiérrez L, Canto-Castro JL, Cervantes VH;

Mexico COVID-19 Critical Care Collaborative Group (2021) Outcomes of patients with COVID-19 in the intensive care unit in Mexico: A multicenter observational study. Heart Lung 50:28-32. https://doi.org/10.1016/j.hrtlng.2020.10.013.

32. Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, Jabaley CS, Carpenter D, Kaplow R, Hernandez-Romieu AC, Adelman MW, Martin GS, Coopersmith CM, Murphy DJ; and the Emory COVID-19 Quality and Clinical Research Collaborative (2020) ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019. Crit Care Med 48:e799-e804. https://doi.org/10.1097/CCM.0000000000004457.
33. Nabors C, Sridhar A, Hooda U, Lobo SA, Levine A, Frishman WH, Dhand A (2021) Characteristics and Outcomes of Patients 80 Years and Older Hospitalized With Coronavirus Disease 2019 (COVID-19). Cardiol Rev 29:39-42. https://doi.org/10.1097/CRD.0000000000000368.
34. Salacup G, Lo KB, Gul F, Peterson E, De Joy R, Bhargav R, Pelayo J, Albano J, Azmaiparashvili Z, Benzaquen S, Patarroyo-Aponte G, Rangaswami J (2021) Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort. J Med Virol 93:416-423. https://doi.org/10.1002/jmv.26252.
35. Nasrullah A, Jayakrishnan T, Wedgeworth P, Mosley M, Vashistha K, Haag A, Bakalov V, Chaturvedi A, Manzi S, Kapetanos A (2021) Characteristics and Outcomes of COVID-19 Patients Admitted to Intensive Care Units in a Large Health System in Western Pennsylvania. Cureus 13:e16552. https://doi.org/10.7759/cureus.16552.

36. Sjöström B, Månsson E, Viklund Kamienny J, Östberg E (2021) Characteristics and definitive outcomes of COVID-19 patients admitted to a secondary hospital intensive care unit in Sweden. Health Sci Rep 4:e446. https://doi.org/10.1002/hsr2.446.
37. Ismail K, Bensasi H, Taha A, Nazir A, Abdelkhalek M, Mohamed W, Lodhe D, Buschbeck S, Bauer M, Sakr Y (2021) Characteristics and outcome of critically ill patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to a tertiary care center in the United Arab Emirates during the first wave of the SARS-CoV-2 pandemic. A retrospective analysis. PLoS One 16:e0251687. https://doi.org/10.1371/journal.pone.0251687.
38. Ofosu-Barko K, Liu Y, Alkhatib Tamimi F, Al Husami W, Ganatra S, Resnic F, Shah SP (2021) Angiotensin II Administration in Patients With COVID-19 Shock. Crit Pathw Cardiol 20:100-102. https://doi.org/10.1097/HPC.0000000000000246.
39. Ramkumar R, Rani D, Bhattacharjee S, Aggarwal R, Soni KD, Aravindan A, Gupta A, Ayub A, Prakash K, Ganesh V, Trikha A (2021) Epidemiology and clinical characteristics of COVID- 19 patients requiring critical care in a Tertiary care teaching hospital. J Anaesthesiol Clin Pharmacol 37:366-370. https://doi.org/10.4103/joacp.JOACP_585_20.
40. Biccard BM, Miller M, Michell WL, Thomson D, Ademuyiwa A, Aniteye E, et al; ACCCOS Investigators (2021). Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet 397:1885-1894. https://doi.org/10.1016/S0140-6736(21)00441-4.

41. Mammen JJ, Kumar S, Thomas L, Kumar G, Zachariah A, Jeyaseelan L, Peter JV, Agarwal A, Mukherjee A, Chatterjee P, Bhatnagar T, Rasalam JE, Chacko B, Mani T, Joy M, Rupali P, Murugesan M, Daniel D, Latha B, Bundas S, Kumar V, Dosi R, Khambholja JR, de Souza R, Chander BT, Bahadur S, Dube S, Suri A, Jindal A, Shrivastav O, Barge V, Bajpayee A, Malhotra P, Singh N, Tambe M, Sharma N, Bhat S, Kaulgud RS, Gurtoo A, Reddy DH, Upadhyay K, Jain A, Patel TC, Nagori I, Jha PR, Babu KVS, Aparna C, Panjwani SJ, Natarajan M, Baldi M, Khadke VK, Dua S, Singh R, Sharma A, Sharma J, Gokhale YA, Yadav PD, Sapkal G, Kaushal H, Kumar VS (2021) Factors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial. BMJ Open 11:e050571. https://doi.org/10.1136/bmjopen-2021-050571.
42. Andrade JA, Muzykovsky K, Truong J (2021) Risk factors for mortality in COVID-19 patients in a community teaching hospital. J Med Virol 93:3184-3193. https://doi.org/10.1002/jmv.26885.
43. Chand S, Kapoor S, Orsi D, Fazzari MJ, Tanner TG, Umeh GC, Islam M, Dicpinigaitis PV (2020) COVID-19-Associated Critical Illness-Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center. J Intensive Care Med 35:963-970. https://doi.org/10.1177/0885066620946692.
44. Bezerra R, Teles F, Mendonca PB, Damte T, Likaka A, Ferrer-Miranda E, Albuquerque JO, de Lima Filho JL (2021) Outcomes of critically ill patients with acute kidney injury in COVID-19 infection: an observational study. Ren Fail 43:911-918. https://doi.org/10.1080/0886022X.2021.1933530.

45. Dang MKM, Bhatt I, Dulu AO, Zhang H, Kostelecky N, Pastores SM (2021) Clinical Characteristics, Management, and Outcomes of Cancer Patients With Coronavirus Disease 2019 Admitted to the ICU. Crit Care Explor 3:e0535. https://doi.org/10.1097/CCE.0000000000000535.
46. Gündoğan K, Akbudak İH, Hancı P, Halaçlı B, Temel Ş, Güllü Z, İnci K, Bilir Y, Bozkurt FT, Yıldırım F, Şimşek M, Yüksel RC, Eren E, Altıntaş ND, Talan L, Elay G, Güven G, Kara İ, Aydın E, Yılmaz S, Mengi T, Sarı S, Akbaş T, Acar Cinleti B, Ateş Ayhan N, Aral Özbek D, Şahin TK, Açıkgöz A, Esbah AÜ, Fırat A, Aydemir F, Gürkök MÇ, Zerman A, Gümüş A, Türkoğlu M, Aydoğdu M, Ulu R, Çelik JB, Balcı C, Kıraklı C, Karakoç E, Özyılmaz E, Ortaç Ersoy E, Öcal S, Akın Şen İ, Tor İH, Cömert B, Ergan B, Saraçoğlu KT, Ergil J, Yüksel ÜG, Tutar N, Sungur M, Topeli A (2021) Clinical Outcomes and Independent Risk Factors for 90-Day Mortality in Critically Ill Patients with Respiratory Failure Infected with SARS-CoV-2: A Multicenter Study in Turkish Intensive Care Units. Balkan Med J 38:296-303. https://doi.org/10.5152/balkanmedj.2021.21188.
47. Estella Á, Garcia Garmendia JL, de la Fuente C, Machado Casas JF, Yuste ME, Amaya Villar R, Estecha MA, Yaguez Mateos L, Cantón Bulnes ML, Loza A, Mora J, Fernández Ruiz L, Díez Del Corral Fernández B, Rojas Amezcua M, Rodriguez Higueras MI, Díaz Torres I, Recuerda Núñez M, Zaheri Beryanaki M, Rivera Espinar F, Matallana Zapata DF, Moreno Cano SG, Gimenez Beltrán B, Muñoz N, Sainz de Baranda Piñero A, Bustelo Bueno P, Moreno Barriga E, Rios Toro JJ, Pérez Ruiz M, Gómez González C, Breval Flores A, de San José Bermejo Gómez A, Ruiz Cabello Jimenez MA, Guerrero Marín M, Ortega Ordiales A, Tejero-Aranguren J, Rodriguez Mejías

C, Gomez de Oña J, de la Hoz C, Ocaña Fernández D, Ibañez Cuadros S, Garnacho Montero J; Work Group of Infectious Disease (GTEI) de la Sociedad Andaluza de Medicina Intensiva y Unidades coronarias SAMIUC (2021) Predictive factors of six-week mortality in critically ill patients with SARS-CoV-2: A multicenter prospective study. Med Intensiva (Engl Ed) 46:179-191. https://doi.org/10.1016/j.medin.2021.02.013.

48. Gadhiya KP, Hansrivijit P, Gangireddy M, Goldman JD (2021) Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. BMJ Open 11:e042549. https://doi.org/10.1136/bmjopen-2020-042549.
49. Serpa Neto A, Landoni G, Ostermann M, Lumlertgul N, Forni L, Alvarez-Belon L, Trapani T, Alliegro PV, Zacharowski K, Wiedenbeck C, de Backer D, Bellomo R (2022) Angiotensin II infusion in COVID-19: An international, multicenter, registry-based study. J Med Virol 94:2079-2088. https://doi.org/10.1002/jmv.27592.
50. Brandão Neto RA, Marchini JF, Marino LO, Alencar JCG, Lazar Neto F, Ribeiro S, Salvetti FV, Rahhal H, Gomez Gomez LM, Bueno CG, Faria CC, da Cunha VP, Padrão E, Velasco IT, de Souza HP; Emergencia USP Covid group (2021) Mortality and other outcomes of patients with coronavirus disease pneumonia admitted to the emergency department: A prospective observational Brazilian study. PLoS One 16:e0244532. https://doi.org/10.1371/journal.pone.0244532.
51. Leisman DE, Mastroianni F, Fisler G, Shah S, Hasan Z, Narasimhan M, Taylor MD, Deutschman CS (2020) Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019-Induced Vasodilatory Shock: A

Retrospective Matched Cohort Study. Crit Care Explor 2:e0230. https://doi.org/10.1097/CCE.0000000000000230.

52. Burrell AJ, Pellegrini B, Salimi F, Begum H, Broadley T, Campbell LT, Cheng AC, Cheung W, Cooper DJ, Earnest A, Erickson SJ, French CJ, Kaldor JM, Litton E, Murthy S, McAllister RE, Nichol AD, Palermo A, Plummer MP, Ramanan M, Reddi BA, Reynolds C, Trapani T, Webb SA, Udy AA (2021) Outcomes for patients with COVID-19 admitted to Australian intensive care units during the first four months of the pandemic. Med J Aust 214:23-30. https://doi.org/10.5694/mja2.50883.
53. Qian Z, Lu S, Luo X, Chen Y, Liu L (2021) Mortality and Clinical Interventions in Critically ill Patient With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 8:635560. https://doi.org/10.3389/fmed.2021.635560.
54. Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, Spoto S, Rutjes AWS, Di Nisio M (2020) Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care 24:389. https://doi.org/10.1186/s13054-020-03022-1.
55. Jasiński T, Stefaniak J (2020) COVID-19 and haemodynamic failure: a point of view on mechanisms and treatment. Anaesthesiol Intensive Ther 52:409-417. https://doi.org/10.5114/ait.2020.101813.
56. Luo P, Liu D, Li J (2021) Epinephrine use in COVID-19: friend or foe? Eur J Hosp Pharm 28:e1. https://doi.org/10.1136/ejhpharm-2020-002295.
57. Leisman DE, Mehta A, Li Y, Kays KR, Li JZ, Filbin MR, Goldberg MB (2021) Vasopressin infusion in COVID-19 critical illness is not associated

with impaired viral clearance: a pilot study. Br J Anaesth 127:e146-e148. https://doi.org/10.1016/j.bja.2021.07.005.

58. Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu L, Siu KL, Fung SY, Yung S, Chan TM, To KK, Chan JF, Cai Z, Lau SKP, Chen Z, Jin DY, Woo PCY, Yuen KY (2021) Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 184:2212-2228.e12. https://doi.org/10.1016/j.cell.2021.02.053.
59. Gregoriano C, Molitor A, Haag E, Kutz A, Koch D, Haubitz S, Conen A, Bernasconi L, Hammerer-Lercher A, Fux CA, Mueller B, Schuetz P (2021) Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study. J Endocr Soc 5:bvab045. https://doi.org/10.1210/jendso/bvab045.
60. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM (2014) Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension 64:1368-1375. https://doi.org/10.1161/HYPERTENSIONAHA.114.03743.
61. Pan M, Vasbinder A, Anderson E, Catalan T, Shadid HR, Berlin H, Padalia K, O'Hayer P, Meloche C, Azam TU, Khaleel I, Michaud E, Blakely P, Bitar A, Huang Y, Zhao L, Pop-Busui R, Loosen SH, Chalkias A, Tacke F, Giamarellos-Bourboulis EJ, Reiser J, Eugen-Olsen J, Hayek SS; ISIC Group (2021) Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. J Am Heart Assoc 10:e023535. https://doi.org/10.1161/JAHA.121.023535.

62. Bendjelid K (2020) Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? Crit Care 24:407. https://doi.org/10.1186/s13054-020-03144-6.
63. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, Zangrillo A, Landoni G (2015) The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 115:656-675. https://doi.org/10.1093/bja/aev284.
64. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Müllner M, Herkner H (2016) Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2:CD003709. https://doi.org/10.1002/14651858.CD003709.pub4.
65. Favaron E, Ince C, Hilty MP, Ergin B, van der Zee P, Uz Z, Wendel Garcia PD, Hofmaenner DA, Acevedo CT, van Boven WJ, Akin S, Gommers D, Endeman H (2021) Capillary Leukocytes, Microaggregates, and the Response to Hypoxemia in the Microcirculation of Coronavirus Disease 2019 Patients. Crit Care Med 49:661-670. https://doi.org/10.1097/CCM.0000000000004862.
66. Di Dedda U, Ascari A, Fantinato A, Fina D, Baryshnikova E, Ranucci M (2022) Microcirculatory Alterations in Critically Ill Patients with COVID-19-Associated Acute Respiratory Distress Syndrome. J Clin Med 11:1032. https://doi.org/10.3390/jcm11041032.
67. Kanoore Edul VS, Caminos Eguillor JF, Ferrara G, Estenssoro E, Siles DSP, Cesio CE, Dubin A (2021) Microcirculation alterations in severe COVID-19 pneumonia. J Crit Care 61:73-75. https://doi.org/10.1016/j.jcrc.2020.10.002.
68. Çalışkan M, Baycan ÖF, Çelik FB, Güvenç TS, Atıcı A, Çağ Y, Konal O, İrgi T, Bilgili ÜZ, Ağırbaşlı MA (2022) Coronary microvascular dysfunction is

common in patients hospitalized with COVID-19 infection. Microcirculation 18:e12757. https://doi.org/10.1111/micc.12757.

69. Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse PR, Fobker M, Kühn J, Braune S, Göbel U, Thölking G, Gröschel A, Pavenstädt H, Vink H, Kümpers P (2021) Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis 24:145-157. https://doi.org/10.1007/s10456-020-09753-7.
70. do Espírito Santo DA, Lemos ACB, Miranda CH (2020) In vivo demonstration of microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 50:790-794. https://doi.org/10.1007/s11239-020-02245-x.
71. Dubin A, Pozo MO, Casabella CA, Pálizas F Jr, Murias G, Moseinco MC, Kanoore Edul VS, Pálizas F, Estenssoro E, Ince C (2009) Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care 13:R92. https://doi.org/10.1186/cc7922.
72. Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J, de Vries CJ, Biessen EA, van Berkel TJ, Pannekoek H, Horrevoets AJ (2005) Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 167:609-618. https://doi.org/10.1016/S0002-9440(10)63002-7.
73. Lupu F, Kinasewitz G, Dormer K (2020) The role of endothelial shear stress on haemodynamics, inflammation, coagulation and glycocalyx during sepsis. J Cell Mol Med 24:12258-12271. https://doi.org/10.1111/jcmm.15895.
74. Chalkias A, Xanthos T, Papageorgiou E, Anania A, Beloukas A, Pavlopoulos F (2018) Intraoperative initiation of a modified ARDSNet protocol increases survival of septic patients with severe acute respiratory distress syndrome. Heart Lung 47:616-621. https://doi.org/10.1016/j.hrtlng.2018.06.011.

75. Marik PE (2014) Iatrogenic salt water drowning and the hazards of a high central venous pressure. Ann Intensive Care 4:21. https://doi.org/10.1186/s13613-014-0021-0.

FIGURE LEGENDS

Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram

Fig. 2 Effect of vasopressor use on mortality of critically ill patients with COVID-19

Fig. 3 Effect of vasopressor use on the incidence of acute kidney injury

Fig. 4 Subgroup analyses were performed based on the definition of acute kidney injury

APPENDIX LEGENDS

Appendix A: PRISMA checklist.

Appendix B: Algorithms used for all databases.

Appendix C1: Definitions used for AKI and mortality follow-up time points.

Appendix C2: Angiotensin-related data.

Appendix C3: MINORS results for each study.

Appendix D1: Funnel plot for mortality meta-analysis.

Appendix D2: Funnel plot for AKI meta-analysis.

Figure 1


Identification of studies via databases and registers
Identification
Records identified from*:
Databases (n = 975)
Pubmed (n = 559)
Scopus (n = 401)
Clinicaltrials.gov (n = 15)
Manually (n = 1)
Records removed *before screening*:
Duplicate records removed
(n = 167)
Screening
Records screened
(n = 809)
Records excluded**
(n = 722)
Reports sought for retrieval
(n = 87)
Reports not retrieved
(n = 0)
Reports assessed for eligibility
(n = 87)
Reports excluded:
No population of interest (n = 3)
No intervention of interest (n = 4)
No outcome of interest (n = 47)
Included
Studies included in review
(n = 33)

Figure 2

Study or Subgroup	Vasopressors Events	Vasopressors Total	No vasopressors Events	No vasopressors Total	Weight	Risk Ratio IV, Random, 95% CI
Ghosn	27	66	3	44	3.4%	6.00 [1.94, 18.58]
De Menezes – Neves	16	17	1	41	1.8%	38.59 [5.55, 268.41]
Namendys – Silva	70	139	15	25	5.9%	0.84 [0.59, 1.20]
Auld	56	143	6	74	4.5%	4.83 [2.18, 10.68]
Nabors	21	23	11	64	5.3%	5.31 [3.06, 9.23]
Salacup	36	49	16	193	5.5%	8.86 [5.38, 14.59]
Nasrulah	14	24	5	34	4.2%	3.97 [1.65, 9.54]
Sjostorm	16	40	0	13	1.0%	11.27 [0.72, 175.79]
Ismail	74	176	1	195	1.7%	81.99 [11.52, 583.59]
Ramkumar	25	29	5	31	4.4%	5.34 [2.36, 12.08]
Biccard	748	931	724	2155	6.4%	2.39 [2.24, 2.56]
Mammen	17	18	48	433	6.1%	8.52 [6.38, 11.38]
Andrade	52	63	33	221	6.0%	5.53 [3.96, 7.72]
Chand	141	233	16	67	5.7%	2.53 [1.63, 3.93]
Bezzera	310	325	72	99	6.4%	1.31 [1.16, 1.48]
Gundogan	152	173	80	248	6.3%	2.72 [2.26, 3.29]
Dang	34	63	6	36	4.6%	3.24 [1.51, 6.96]
Estella	143	333	9	89	5.0%	4.25 [2.26, 7.99]
Gadhiya	34	53	21	230	5.6%	7.03 [4.46, 11.07]
Bradao – Neto	114	153	39	353	6.0%	6.74 [4.95, 9.20]
Burrell	24	111	6	93	4.3%	3.35 [1.43, 7.85]
Total (95% CI)		**3162**		**4738**	**100.0%**	**4.26 [3.15, 5.76]**
Total events	2124		1117			

Heterogeneity: $Tau^2 = 0.37$; $Chi^2 = 358.62$, df = 20 ($P < 0.00001$); $I^2 = 94\%$
Test for overall effect: Z = 9.43 ($P < 0.00001$)



Figure 3

Study or Subgroup	Vasopressors Events	Vasopressors Total	No vasopressors Events	No vasopressors Total	Weight	Risk Ratio IV, Random, 95% CI
Pelayo	35	42	75	181	13.0%	2.01 [1.61, 2.51]
Lowe	33	49	3	32	6.0%	7.18 [2.40, 21.47]
Hansrivijit	44	53	70	230	13.0%	2.73 [2.17, 3.43]
Ghosn	42	66	8	44	9.4%	3.50 [1.82, 6.72]
Farooqui	207	249	162	779	13.4%	4.00 [3.45, 4.64]
De Menezes – Neves	42	54	12	41	10.9%	2.66 [1.62, 4.37]
Bernardo	14	18	316	526	12.8%	1.29 [1.00, 1.67]
Hardenberg	66	95	4	128	6.8%	22.23 [8.40, 58.86]
Geri	123	195	72	214	13.1%	1.87 [1.51, 2.33]
Bezzera	325	424	0	99	1.5%	153.18 [9.64, 2433.19]
Total (95% CI)		**1245**		**2274**	**100.0%**	**3.17 [2.21, 4.54]**
Total events	931		722			

Heterogeneity: $Tau^2 = 0.25$; $Chi^2 = 105.97$, df = 9 ($P < 0.00001$); $I^2 = 92\%$
Test for overall effect: Z = 6.28 ($P < 0.00001$)



Figure 4

Study or Subgroup	Vasopressors Events	Vasopressors Total	No vasopressors Events	No vasopressors Total	Weight	Risk Ratio IV, Random, 95% CI
4.1.1 KDIGO All stages						
Pelayo	35	42	75	181	13.0%	2.01 [1.61, 2.51]
Lowe	33	49	3	32	6.0%	7.18 [2.40, 21.47]
Hansrivijit	44	53	70	230	13.0%	2.73 [2.17, 3.43]
De Menezes – Neves	42	54	12	41	10.9%	2.66 [1.62, 4.37]
Bernardo	14	18	316	526	12.8%	1.29 [1.00, 1.67]
Geri	123	195	72	214	13.1%	1.87 [1.51, 2.33]
Bezzera	325	424	0	99	1.5%	153.18 [9.64, 2433.19]
Subtotal (95% CI)		**835**		**1323**	**70.3%**	**2.29 [1.67, 3.14]**
Total events	616		548			
Heterogeneity: $Tau^2 = 0.12$; $Chi^2 = 34.29$, df = 6 (P < 0.00001); $I^2 = 83\%$						
Test for overall effect: Z = 5.16 (P < 0.00001)						
4.1.2 Only KDIGO stages 2–3						
Ghosn	42	66	8	44	9.4%	3.50 [1.82, 6.72]
Hardenberg	66	95	4	128	6.8%	22.23 [8.40, 58.86]
Subtotal (95% CI)		**161**		**172**	**16.3%**	**8.50 [1.39, 51.97]**
Total events	108		12			
Heterogeneity: $Tau^2 = 1.53$; $Chi^2 = 9.55$, df = 1 (P = 0.002); $I^2 = 90\%$						
Test for overall effect: Z = 2.32 (P = 0.02)						
4.1.3 Definition of AKI not available						
Farooqui	207	249	162	779	13.4%	4.00 [3.45, 4.64]
Subtotal (95% CI)		**249**		**779**	**13.4%**	**4.00 [3.45, 4.64]**
Total events	207		162			
Heterogeneity: Not applicable						
Test for overall effect: Z = 18.35 (P < 0.00001)						
Total (95% CI)		**1245**		**2274**	**100.0%**	**3.17 [2.21, 4.54]**
Total events	931		722			
Heterogeneity: $Tau^2 = 0.25$; $Chi^2 = 105.97$, df = 9 (P < 0.00001); $I^2 = 92\%$						
Test for overall effect: Z = 6.28 (P < 0.00001)						
Test for subgroup differences: $Chi^2 = 10.69$, df = 2 (P = 0.005), $I^2 = 81.3\%$						



Table 1. Main characteristics of the included studies

Authors Country, YOP Study Design	Department	Number of patients (Received vasopressors / All [%])	Age Mean ± SD / Median (IQR)	Male (%) / Female (%)
Ionescu et al. USA, 2021 Retrospective	ICU	191 / 281 (68 %)	61 ± 13.9	154 (54.8%) / 127 (45.2%)
Pelayo et al. USA, 2020 Retrospective	ICU + HDU	42 / 223 (18.8 %)	65.91 ± 14.95	116 (52%) / 107 (48%)
Lowe et al. UK, 2021 Retrospective	ICU	49 / 81 (60.5 %)	57 ± 18	50 (61.7%) / 31 (38.3%)
Hansrivijit et al. USA, 2021 Retrospective	ICU + HDU	53 / 283 (18.7 %)	64.1 ± 15.9	159 (56.2%) / 124 (43.8%)
Mesquida et al. Spain/Mexico/Brazil, 2021 Prospective	ICU + IRCU	12 / 71 (16.9 %)	59 ± 13	51 (69.9%) / 22 (30.1%)
Ghosn et al. UAE, 2021 Retrospective	ICU	66 / 110 (60 %)	50 (40-59)	98 (89.1%) / 12 (10.9%)
Farooqui et al. Saudi Arabia, 2021 Retrospective	ICU + HDU	249 / 1025 (24.3 %)	55.8 ± 18.52	582 (56.8%) / 443 (43.2%)
de Menezes Neves et al. Brazil, 2021	ICU	54 / 95 (56.8 %)	64.9 ± 15.1	61 (64.2%) / 34 (35.8%)

Retrospective				
Bernardo et al. Portugal, 2021 Retrospective	HDU	18 / 544 (3.3 %)	68.9 ± 17.9	298 (54.8%) / 246 (45.2%)
Hardenberg et al. Germany, 2021 Retrospective	HDU	95 / 223 (42.6 %)	62 (51-75)	147 (65.9%) / 76 (34.1%)
Geri et al. France, 2021 Retrospective	ICU	165 / 379 (43.5 %)	62 (53.69)	291 (76.8%) / 88 (23.2%)
Namendys-Silva et al. Mexico, 2021 Retrospective	ICU	139 / 164 (84.8 %)	57.3 ± 13.7	114 (69.5%) / 50 (30.5%)
Auld et al. USA, 2021 Retrospective	ICU	143 / 217 (65.9 %)	64 (54-73)	119 (54.8%) / 98 (45.2%)
Nabors et al. USA, 2021 Retrospective	HDU	23 / 87 (26.4 %)	86 (80-105)	48 (55.2%) / 39 (44.8%)
Salacup et al. USA, 2021 Retrospective	HDU	49 / 242 (20.2 %)	66 (58-76)	123 (50.8%) / 119 (49.2%)
Nasrulah et al. USA, 2021 Retrospective	ICU	24 / 58 (41.4 %)	62 (54-73)	37 (63.8%) / 21 (36.2%)
Sjostorm et al. Sweden, 2021 Prospective	ICU	40 / 53 (75.5 %)	59 (33-76)	39 (73.6%) / 14 (26.4%)

Ismail et al. UAE, 2021 Retrospective	ICU	176 / 371 (47.4 %)	53 ± 13	314 (84.6%) / 57 (15.4%)
Osofu-Barko et al.* USA, 2021 Retrospective	ICU	10 / Not available	64.5 ± 6.15	9 (90%) / 1 (10%)
Ramkumar et al. India, 2021 Prospective	ICU	29 / 60 (48.3 %)	50 (37.5-63)	42 (70%) / 18 (30%)
Biccard et al. (ACCCOS) Africa**, 2021 Prospective	ICU + HDU	931 / 3086 (30.2 %)	56 ± 16.11	1890 (60.6%) / 1228 (39.4%)
Mammen et al. India, 2021 Secondary analysis of RCT	ICU + HDU	18 / 451 (4 %)	51 ± 12.4	346 (76.7%) / 105 (23.3%)
Andrade et al. USA, 2021 Retrospective	HDU	63 / 284 (22.2 %)	67 ± 14.5	155 (54.6%) / 129 (45.4%)
Chand et al. USA, 2020 Retrospective	ICU	233 / 300 (77.7 %)	58.2 ± 12.6	182 (60.7%) / 118 (39.3%)
Bezzera et al. Brazil, 2021 Retrospective	ICU	325 / 424 (76.7 %)	66.42 ± 13.79	251 (59.2%) / 173 (40.8%)
Gundogan et al. Turkey, 2021 Retrospective	ICU	173 / 421 (41.1 %)	67 (57-76)	251 (59.6%) / 170 (40.4%)
Dang et al.	ICU	63 / 89 (70.8 %)	65 (57-70)	52 (58.4%) / 37 (41.6%)

USA, 2021 Retrospective				
Estella et al. Spain, 2021 Prospective	ICU	419 / 422 (99.3 %)	63 (54-71)	305 (72.3%) / 117 (27.7%)
Gadhiya et al. USA, 2021 Retrospective	ICU + HDU	53 / 283 (18.7 %)	64.1 ± 15.9	159 (56.2%) / 124 (43.8%)
Brandão Neto et al. Brazil, 2021 Prospective	ED and then transferred to ICU + HDU	179 / 506 (35.4 %)	60.1 ± 15.1	290 (57.3%) / 216 (42.7%)
Burrell et al. Australia, 2021 Prospective	ICU	111 / 204 (54.4 %)	63.5 (53-72)	140 (68.6%) / 64 (31.4%)
Leisman et al.* USA, 2020 Retrospective	ICU + HDU	10 / 29 (34.5 %)	56 ± 14	19 (65.5%) / 10 (34.5%)
Serpa Neto et al.* Multicentric study, 2022 Prospective	ICU + HDU	65 / 132 (49.2 %)	61 (53-67)	105 (79.5%) / 27 (20.5%)

Abbreviations. YOP: Year of Publication; SD: Standard Deviation; IQR: Interquartile Range; USA: United States of America; ICU: Intensive Care Unit; HDU: High Dependency Unit; UK: United Kingdom; IRCU: Intensive Respiratory Care Unit; UAE: United Arab Emirates; ED: Emergency Department.

* These studies only included patients that received angiotensin-II.

**10 African Countries.

Table 2. Data on mortality based on major vasopressors

Authors Country, YOP Study Design	Intervention Group: Deaths / All (%)	Comparator Group: Deaths / All (%)
Chand et al. USA, 2020 Retrospective	Any vasopressor support: 141 / 233 (61%) Norepinephrine ± other vasopressors: 138 / 226 (61%) Phenylephrine ± other vasopressors: 53 / 89 (60%) Vasopressin ± other vasopressors: 81 / 104 (78%) Epinephrine ± other vasopressors: 19 / 25 (76%)	No vasopressor support: 16 / 67 (24%)
Leisman et al. USA, 2020 Retrospective	Angiotensin-II ± other vasopressors: 4 / 10 (40%)	Other vasopressors: 10 / 19 (53%)
Serpa Neto et al. Multicentric study, 2022 Prospective	Angiotensin-II ± norepinephrine: 35 / 65 (54%)	Other vasopressors: 27 / 67 (40%)
Ofosu-Barko et al. USA, 2021 Retrospective	Angiotensin-II + other vasopressors: 4 / 10 (40%)	-